August 2020 Midatech Pharma PLC ("Midatech" or the "Company") Registration Statement on Form F-1 Declared Effective May 2020 UK Warrants Now Exercisable Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery tec

("Midatech" or the "Company")

Statement on Form F-1 Declared Effective

May 2020 UK Warrants Now Exercisable

Midatech Pharma PLC (AIM: MTPH.L;

Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces

that the U.S. Securities and Exchange Commission ("SEC") has declared effective the Company's registration statement

on Form F-1 (the "Registration Statement") relating to the permitted resale of up to 12,695,445 ordinary shares, nominal

value 0.1p each, in the Company ("Ordinary Shares") represented by 2,539,091 American Depositary Shares (the "ADSs")

held by certain stockholders of the Company named in the registration statement that are issuable upon the exercise of previously

issued warrants as follows:

May 2020, warrants were issued to certain UK investors in respect 3,213,957 Ordinary Shares exercisable at 0.34 per share.

These warrants became exercisable upon the effectiveness of the Registration Statement.

Statement, while effective, allows the stockholders named in the Registration Statement to publicly resell the ADSs or Ordinary

Shares. The Company will not receive any proceeds from the sale of the ADSs or Ordinary Shares by the stockholders. Upon the cash

exercise of the warrants, the Company will receive the exercise price of the warrants.

Statement may be accessed through the SEC's website at www.sec.gov. A copy of the prospectus

relating to the offering may also be accessed through the SEC's website at www.sec.gov.

shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities,

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such state or jurisdiction.

For more information,

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving bio-delivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's technologies are supported

by 36 patent families including 120 granted patents and an additional 70 patent applications.

Midatech's headquarters and R&D

facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements

Certain statements in this press release

may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States

Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical

fact should be considered forward-looking statements, including, but not limited to, any payments that may be received as a result

of the exercise of the warrants.

Reference should be made to those documents

that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange

AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations

promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause

actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking

statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning

Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM

Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to

publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.